Advanced

Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)

Abshire, T. C.; Federici, A. B.; Alvarez, M. T.; Bowen, J.; Carcao, M. D.; Gill, J. Cox; Key, N. S.; Kouides, P. A.; Kurnik, K. and Lail, A. E., et al. (2013) In Haemophilia 19(1). p.76-81
Abstract
The bleeding patterns of severe von Willebrand's disease (VWD) adversely affect quality of life, and may be life threatening. There is a presumed role for prophylaxis with VWF-containing concentrates, but data are scarce. The von Willebrand Disease Prophylaxis Network (VWD PN) was formed to investigate the role of prophylaxis in clinically severe VWD that is not responsive to other treatment(s). Using a retrospective design, the effect of prophylaxis was studied. Availability of records to document, or reliably assess, the type and frequency of bleeding episodes prior to, and after, the initiation of prophylaxis was required. Annualized bleeding rates were calculated for the period prior to prophylaxis, during prophylaxis and by primary... (More)
The bleeding patterns of severe von Willebrand's disease (VWD) adversely affect quality of life, and may be life threatening. There is a presumed role for prophylaxis with VWF-containing concentrates, but data are scarce. The von Willebrand Disease Prophylaxis Network (VWD PN) was formed to investigate the role of prophylaxis in clinically severe VWD that is not responsive to other treatment(s). Using a retrospective design, the effect of prophylaxis was studied. Availability of records to document, or reliably assess, the type and frequency of bleeding episodes prior to, and after, the initiation of prophylaxis was required. Annualized bleeding rates were calculated for the period prior to prophylaxis, during prophylaxis and by primary bleeding indication defined as the site accounting for more than half of all bleeding symptoms. The Wilcoxon signed-rank test of differences in the medians was used. Sixty-one subjects from 20 centres in 10 countries were enrolled. Data for 59 were used in the analysis. The median age at onset of prophylaxis was 22.4 years. Type 3 VWD accounted for the largest number (N = 34, 57.6%). Differences in bleeding rates within individuals during compared with before prophylaxis were significant for the total group (P < 0.0001), and for those with primary bleeding indications of epistaxis (P = 0.0005), joint bleeding (P = 0.002) and GI bleeding (P = 0.001). The effect of prophylaxis was similar among those age < 18 years and those >= 18. One person developed an inhibitor during treatment. We conclude that prophylactic treatment of VWD is efficacious. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
bleeding rate, epistaxis, gastrointestinal bleeding, joint bleeding, prophylaxis, severe VWD
in
Haemophilia
volume
19
issue
1
pages
76 - 81
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000314827200019
  • scopus:84870998006
ISSN
1351-8216
DOI
10.1111/j.1365-2516.2012.02916.x
language
English
LU publication?
yes
id
e05b32d0-f8ba-481d-aabc-3f2c9b96967a (old id 3589783)
date added to LUP
2013-04-02 07:46:08
date last changed
2019-09-11 01:22:07
@article{e05b32d0-f8ba-481d-aabc-3f2c9b96967a,
  abstract     = {The bleeding patterns of severe von Willebrand's disease (VWD) adversely affect quality of life, and may be life threatening. There is a presumed role for prophylaxis with VWF-containing concentrates, but data are scarce. The von Willebrand Disease Prophylaxis Network (VWD PN) was formed to investigate the role of prophylaxis in clinically severe VWD that is not responsive to other treatment(s). Using a retrospective design, the effect of prophylaxis was studied. Availability of records to document, or reliably assess, the type and frequency of bleeding episodes prior to, and after, the initiation of prophylaxis was required. Annualized bleeding rates were calculated for the period prior to prophylaxis, during prophylaxis and by primary bleeding indication defined as the site accounting for more than half of all bleeding symptoms. The Wilcoxon signed-rank test of differences in the medians was used. Sixty-one subjects from 20 centres in 10 countries were enrolled. Data for 59 were used in the analysis. The median age at onset of prophylaxis was 22.4 years. Type 3 VWD accounted for the largest number (N = 34, 57.6%). Differences in bleeding rates within individuals during compared with before prophylaxis were significant for the total group (P &lt; 0.0001), and for those with primary bleeding indications of epistaxis (P = 0.0005), joint bleeding (P = 0.002) and GI bleeding (P = 0.001). The effect of prophylaxis was similar among those age &lt; 18 years and those &gt;= 18. One person developed an inhibitor during treatment. We conclude that prophylactic treatment of VWD is efficacious.},
  author       = {Abshire, T. C. and Federici, A. B. and Alvarez, M. T. and Bowen, J. and Carcao, M. D. and Gill, J. Cox and Key, N. S. and Kouides, P. A. and Kurnik, K. and Lail, A. E. and Leebeek, F. W. G. and Makris, M. and Mannucci, P. M. and Winikoff, R. and Berntorp, Erik},
  issn         = {1351-8216},
  keyword      = {bleeding rate,epistaxis,gastrointestinal bleeding,joint bleeding,prophylaxis,severe VWD},
  language     = {eng},
  number       = {1},
  pages        = {76--81},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)},
  url          = {http://dx.doi.org/10.1111/j.1365-2516.2012.02916.x},
  volume       = {19},
  year         = {2013},
}